当前位置:循环首页>正文

[ESC2011]左主干冠脉病变的治疗选择——Eeckhout 博士专访

作者:  Eeckhout   日期:2011/8/30 16:53:37

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

<International Circulation>: Treatment option for left main and multivessel coronary artery desease has been a hot topic for many years, the landmark SYNTAX study have provided significant implications, would you please summarize the major principle to which we should adhere when making the choice between CABG and PCI for patients with left main and multi-vessel coronary artery desease?

    <International Circulation>:  Have we had any new generation of drug-eluting stent platform which will possibly improve the outcome of PCI in treating this group of patients?

  《国际循环》:在这类患者的治疗中,新一代药物洗脱支架平台是否可能改善PCI的结果?

    Dr. Eeckhout: Like I mentioned before, bio-absorbable stent is not any longer just a stent because it is a scaffolding device that disappears over time. This is certainly a key progress. In the meantime, we will see at this congress some reports on the fact that late thrombosis has virtually disappeared with newer generation drug eluting stents. I refer to the everolimus drug eluting stent, the Biolimus A9 that uses the bio-absorbable coating technology, all of these devices in my humble opinion improve the<

上一页  [1]  [2]  [3]  [4]  

版面编辑:沈会会  责任编辑:张衡



左主干冠脉病变SYNTAXCABG PCITAVI

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530